Healios Aims to Ready Stem-Cell Therapy for Eyesight By 2020
This article is for subscribers only.
Healios K.K., which is using Nobel Prize-winning technology to develop a treatment for an eye disease that causes vision loss, aims to begin testing it in patients in 2017 and start selling in Japan in five years.
The Tokyo-based biotechnology company has sufficient funds to cover development costs after raising about 7.3 billion yen ($59 million) from its initial public offering earlier this week, Chief Executive Officer Hardy Kagimoto said in an interview.